Modality
Vaccine
MOA
Cl18.2
Target
WEE1
Pathway
Wnt
FLSLE
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
~Dec 2022
→ ~Mar 2024
Phase 2
Jun 2024
→ Dec 2027
Phase 2Current
NCT03850444
2,060 pts·FL
2024-06→2027-12·Completed
2,060 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-011.7y awayPh2 Data· FL
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2027-12-01 · 1.7y away
FL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03850444 | Phase 2 | FL | Completed | 2060 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 |